Also, the HDAC inhibitor panobinostat was evaluated with bevacizumab in a phase I study with patients affected by high-grade glioma, with promising results (3 PR and 7 SD) and a good tolerability profile [46]. This evidence concerns the gene HDAC9 and central nervous system cancer.